Page last updated: 2024-11-06

talinolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Talinolol is a beta-blocker that was initially developed for the treatment of hypertension. It has been shown to have both antihypertensive and anti-anginal effects. The synthesis of talinolol involves several steps, starting from a substituted benzaldehyde. Talinolol is a potent beta-blocker with high affinity for beta1-adrenergic receptors, which are found in the heart. This selective binding results in a reduction of heart rate and blood pressure. The importance of talinolol lies in its potential to manage cardiovascular diseases like hypertension and angina. It is also being investigated for its potential use in other conditions, such as migraines and diabetes. Research on talinolol continues to explore its therapeutic properties and potential benefits. The study of talinolol is driven by its potential to provide effective treatment for various cardiovascular conditions and its unique pharmacologic profile.'

Cross-References

ID SourceID
PubMed CID68770
CHEMBL ID152067
CHEBI ID135533
SCHEMBL ID78047
MeSH IDM0057914

Synonyms (54)

Synonym
57460-41-0
D07184
talinolol (inn)
NCGC00164542-01
talinolol
(+-)-n-cyclohexyl-n'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)urea
(+-)-1-(p-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea
talinolol [inn]
urea, n-cyclohexyl-n'-(4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-, (+-)-
cordanum
1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane
1-(4-(cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
racemic talinolol
(+-)-talinolol
talinololum [inn-latin]
1-(3-(3-cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol
CHEBI:135533
CHEMBL152067
1-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-3-cyclohexylurea
1-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]-3-cyclohexylurea
38649-73-9
AKOS003382147
A8190
1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea
(+-)-1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylharnstoff
unii-3s82268bkg
talinololum
3s82268bkg ,
dtxcid4026426
cas-57460-41-0
tox21_112171
dtxsid6046426 ,
FT-0674796
gtpl4664
3-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-1-cyclohexylurea
talinolol [who-dd]
talinolol [mi]
talinolol [mart.]
SCHEMBL78047
NCGC00164542-02
tox21_112171_1
F1905-6534
n-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n'-cyclohexylcarbamimidic acid
rac talinolol
sr-01000945249
SR-01000945249-1
bdbm50502344
DB11770
n-{4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-n'-cyclohexylurea
( inverted exclamation marka)-talinolol
Q7679533
BCP30483
cordanum; racemic talinolol
AT33613

Research Excerpts

Overview

Talinolol is a suitable model compound for Pgp drug-drug interaction studies due to its Pgp-related active intestinal secretion and lack of any significant metabolism.

ExcerptReferenceRelevance
"Talinolol is a suitable model compound for Pgp drug-drug interaction studies due to its Pgp-related active intestinal secretion and lack of any significant metabolism."( P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Gramatté, T; Kirch, W; Krappweis, J; Oertel, R; Schwarz, UI, 2000
)
1.26

Pharmacokinetics

A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers. Six days of glycyrrhizin treatment resulted in no significant alterations in the pharmacokinetic parameters. No change in the time to peak concentration (t(max) and the blood elimination half-life ( t(1/2) were observed between the placebo- and silymarin-treated phases.

ExcerptReferenceRelevance
" The pharmacodynamic study was performed according to an original technique consisting in a sequence of monitored repeated identical treadmill exercise."( [Comparative pharmacodynamic study of Cordanum and obzidan in stress angina pectoris patients].
Nazarenko, VA; Nikolenko, SA, 1981
)
0.26
" A pharmacokinetic characteristics of new drug adalate SL with two-step liberation of nifedipine."( [The pharmacokinetics of different drug forms of nifedipine when used singly and in a course as monotherapy and in combination with Cordanum and triampur preparations in patients with arterial hypertension].
Ignat'ev, VG; Kukes, VG; Pavlov, SS; Starodubtsev, AK,
)
0.13
" Pharmacokinetic model fits showed that about half of the oral talinolol dose given with and without meal is drained from the intestine via a presystemic storage compartment."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
1.13
" DRUG-KNT--a pharmacokinetic software developed previously for fitting one and two compartment kinetics using the iterative curve stripping method--was modified and a revised subroutine was incorporated to solve double-peak models."( A simple pharmacokinetics subroutine for modeling double peak phenomenon.
Mahmoudian, M; Mirfazaelian, A, 2006
)
0.33
" The terminal half-life of the drug averaged 19."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.33
"Besides minimum input parameters for the compound (pKa(s), solubility at one or more pH's, Peff, doses, formulation, diffusivity), physiological and pharmacokinetic properties, transporter data are included in these predictions."( In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Bolger, MB; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D, 2006
)
0.57
" Pharmacokinetic parameters (AUC, Cmax) from in silico simulations are within acceptable range comparing with data, observed in vivo."( In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Bolger, MB; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D, 2006
)
0.57
" The model developed may be useful in the prediction of absorption of other P-gp substrates including pharmacodynamic consequences."( In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Bolger, MB; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D, 2006
)
0.57
" A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers, the main pharmacokinetic data are as follows: Cmax was 147."( Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study.
He, J; Liu, XL; Peng, WX; Song, J; Su, FL; Tang, J; Terhaag, B; Yang, LY; Zhang, BK; Zhu, YG, 2007
)
0.97
" Non-compartmental analysis was used to characterize talinolol plasma concentration-time profiles, all pharmacokinetic parameters were calculated using DAS: (ver."( Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Bi-Kui, Z; Cong, Z; Fen-Li, S; Feng, W; Jing, T; Juan, H; Juan, S; Rong-Hua, Z; Terhaag, B; Wen-Xing, P, 2007
)
0.81
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"014), respectively, without significant changes in elimination half-life and the time to C(max)."( Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Chen, Y; Fan, L; He, YJ; Hu, DL; Huang, YF; Jiang, F; Lei, HP; Li, Q; Tao, GY; Wang, G; Zhang, W; Zhou, HH, 2009
)
0.59
" No change in the time to peak concentration (t(max)) and the blood elimination half-life (t(1/2)) of talinolol was observed between the placebo- and silymarin-treated phases."( Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Chen, Y; Guo, D; Han, Y; Tan, ZR; Zhou, HH, 2009
)
0.82
"Calibration standards with concentrations over the range of 10-1000 ng ml(-1) were validated for routine sample analysis to support pharmacokinetic studies with talinolol in rats."( Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study.
Bhat, KM; Musmade, PB; Pathak, SM; Udupa, N, 2010
)
0.8
" Six days of glycyrrhizin treatment resulted in no significant alterations in the pharmacokinetic parameters (AUC(0-∞), AUC(0-24), C (max), t (max), t (½)) for talinolol."( Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Cai, HL; Fang, PF; Li, HD; Liu, YP; Tan, QY; Wang, F; Xu, P; Yan, M, 2013
)
0.8
"6% in 5 subjects and cmax was decreased by 29."( Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans - Implications for the evaluation of transporter-mediated flavonoid-drug interactions.
Langguth, P; Nguyen, MA; Staubach, P; Wolffram, S, 2014
)
0.62
"Concomitant administration of P-glycoprotein substrates and inhibitors may cause pharmacokinetic drug interactions leading to increased concentrations associated with serious side effects and toxicities."( Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation.
Okyar, A; Ozturk, D; Ozturk, N; Pala-Kara, Z, 2017
)
0.78
"Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to quantitatively describe drug disposition profiles in vivo, thereby providing an alternative to predict drug-drug interactions (DDIs) that have not been tested clinically."( Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.
Costales, C; Eatemadpour, S; Kimoto, E; Lazzaro, S; Varma, MV; Yamazaki, S, 2019
)
0.51

Compound-Compound Interactions

A specific LC-MS/MS assay was developed for the automated determination of talinolol in human plasma, using on-line solid phase extraction system.

ExcerptReferenceRelevance
" Good response was noted in corinfar-retard combination with Cordanum in patients with moderate hemodynamic changes, hypertonicity of sympathoadrenal system, tachycardia."( [The clinical efficacy of Korinfar-retard in combination with Cordanum, triampur and Capoten in patients with arterial hypertension].
Chil'tsov, VV; Ignat'ev, VG; Kukes, VG; Pavlov, SS; Pavlova, LI; Privalov, AN; Rumiantsev, AS, 1996
)
0.29
" However, this component may take part in vivo and contribute to drug-drug interactions involving P-gp."( pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
Artursson, P; Neuhoff, S; Ungell, AL; Zamora, I, 2003
)
0.32
"A specific LC-MS/MS assay was developed for the automated determination of talinolol in human plasma, using on-line solid phase extraction system (prospekt 2) combined with atmospheric pressure chemical ionization (APCI) tandem mass spectrometry."( Determination of talinolol in human plasma using automated on-line solid phase extraction combined with atmospheric pressure chemical ionization tandem mass spectrometry.
Bourgogne, E; Grivet, C; Hopfgartner, G, 2005
)
0.9
"In this study, we aimed to determine the drug-drug interaction potential between atorvastatin (ATOR), and talinolol (TAL)."( Effects of atorvastatin on talinolol absorption: A potential drug-drug interaction.
Baktir, G; Kara, ZP; Okyar, A; Orman, MN; Ozturk, D; Ozturk, N, 2020
)
1.07

Bioavailability

Oral bioavailability increases after administration of higher doses of talinolol. Rifampicin changes the time course of absorption rate but not the fraction absorbed.

ExcerptReferenceRelevance
"In an open randomized crossover study, the pharmacokinetics and bioavailability of the selective beta 1-adrenoceptor antagonist talinolol (Cordanum--Arzneimittelwerk Dresden GmbH, Germany) were investigated in twelve healthy volunteers (five female, seven male; three poor and nine extensive metabolizers of the debrisoquine hydroxylation phenotype) after intravenous infusion (30 mg) and oral administration (50 mg), respectively."( Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man.
Gramatté, T; Oertel, R; Richter, K; Trausch, B, 1995
)
0.73
"Talinolol oral bioavailability of 55% is due to a low absorption rate and a decrease of absorption capabilities along the small intestine."( Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté, T; Kirch, W; Oertel, R; Terhaag, B, 1996
)
1.95
" bioavailability are of particular interest, also in drug development."( P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Ader, P; Baktir, G; Hanafy, A; Langguth, P; Okyar, A; Radschuweit, A; Spahn-Langguth, H; Terhaag, B, 1998
)
0.5
"This is the first study to show a decreased oral bioavailability of a P-glycoprotein substrate (talinolol) in humans as a result of coadministration of verapamil."( Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Berndt, A; Gramatté, T; Kirch, W; Krappweis, J; Oertel, R; Schwarz, UI; von Richter, O, 1999
)
0.75
" This gives further rationale for P-glycoprotein-mediated intestinal drug secretion as a cause for incomplete oral bioavailability and for drug interactions during intestinal absorption."( Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
Gramatté, T; Oertel, R, 1999
)
0.58
"Increased bioavailability of the P-glycoprotein (Pgp) substrates digoxin and cyclosporin due to erythromycin has been observed in vivo."( P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Gramatté, T; Kirch, W; Krappweis, J; Oertel, R; Schwarz, UI, 2000
)
0.54
"We suggest that the increase in oral bioavailability of talinolol after concomitant erythromycin is caused by increased intestinal net absorption due to Pgp inhibition by erythromycin."( P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Gramatté, T; Kirch, W; Krappweis, J; Oertel, R; Schwarz, UI, 2000
)
0.79
"We observed a significantly increased bioavailability of digoxin with oral coadministration of talinolol, which is most likely caused by competition for intestinal P-glycoprotein."( Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Franke, G; Giessmann, T; Kroemer, HK; Oertel, R; Siegmund, W; Stuhr, M; Terhaag, B; Weinbrenner, A; Westphal, K; Zschiesche, M, 2000
)
0.78
" It is concluded that inhibition of intestinal secretion may contribute to bioavailability enhancement upon GFJ intake."( Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol.
Langguth, P; Spahn-Langguth, H, 2001
)
0.54
"P-glycoprotein (P-gp) is made responsible for the limited oral bioavailability of P-gp substrates like peptidic HIV protease inhibitors (PIs)."( Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Gyémánt, N; Hilgeroth, A; Molnár, J; Richter, M, 2004
)
0.32
" With respect to combined therapeutic application of PIs, compounds like H17 raise hopes for improved bioavailability of poorly absorbed compounds."( Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Gyémánt, N; Hilgeroth, A; Molnár, J; Richter, M, 2004
)
0.32
" Our objective was to analyze the effect of 2 surfactants with different affinity for P-gp in vitro on the intestinal absorption and bioavailability of the P-gp substrate talinolol in humans."( P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Alsenz, J; Bogman, K; Degen, L; Drewe, J; Gutmann, H; Hopfgartner, G; Zysset, Y, 2005
)
0.77
"This in vivo intraduodenal perfusion study showed that low concentrations of TPGS, close to the concentrations that showed P-gp inhibition in vitro, significantly increased the bioavailability of talinolol."( P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Alsenz, J; Bogman, K; Degen, L; Drewe, J; Gutmann, H; Hopfgartner, G; Zysset, Y, 2005
)
0.77
"Evaluation of the double-peak phenomenon during absorption of the beta(1)-selective blocker talinolol relative to paracetamol, which is well absorbed from all parts of the gut, and relative to vitamin A, which is absorbed via the lymphatic pathway."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
1.11
"Bioavailability of talinolol in enteric-coated and rectal capsules was significantly reduced by about 50% and 80%, respectively, despite unchanged bioavailability of paracetamol."( The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Bernsdorf, A; Giessmann, T; Hartmann, V; Modess, C; Mrazek, C; Nagel, S; Siegmund, W; Wegner, D; Weitschies, W; Zschiesche, M, 2005
)
1.22
" As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.33
"The bioavailability of talinolol in term of AUC(0-->infinity) for IR talinolol was approximately twice as high as compared to the administration of the same dose in a controlled-release dosage form."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.64
"The present study demonstrates a considerable loss of bioavailability of drugs that are substrates of intestinal secretory transporters upon their administration in controlled-release dosage forms."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.33
" It was found that oral bioavailability increases after administration of higher doses of talinolol."( In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Bolger, MB; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D, 2006
)
0.79
" SJW reduced the oral talinolol bioavailability by 25% (P=0."( Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Dresser, GK; Glaeser, H; Hanso, H; Hitzl, M; Kim, RB; Kirch, W; Kuhlisch, E; Miehlke, S; Oertel, R; Schwarz, UI, 2007
)
0.87
"We suggest that the reduced bioavailability of talinolol is most probably due to the low intraluminal curcumin concentration, or possibly due to the upregulation of further ATP-binding cassette transporters, such as MRP2, in different tissues."( Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.
Bi-Kui, Z; Cong, Z; Fen-Li, S; Feng, W; Jing, T; Juan, H; Juan, S; Rong-Hua, Z; Terhaag, B; Wen-Xing, P, 2007
)
0.82
" The variant ABCC2 1249G>A (V417I), however, was associated with lower oral bioavailability (P=0."( Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
Caliebe, A; Cascorbi, I; Haenisch, S; May, K; Siegmund, W; Wegner, D, 2008
)
0.55
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The absolute bioavailability (F %) of talinolol in the rats pretreated with morin was significantly higher (89."( Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
Pathak, SM; Udupa, N, 2010
)
0.85
" The genetic variants -24C>T, 1249G>A and 3972C>T are leading to inter-individual differences of bioavailability of various endogenous and exogenous compounds."( Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.
Cascorbi, I; Haenisch, S; Laechelt, S; Ruehmkorf, A; Siegmund, W; Turrini, E, 2011
)
0.37
" The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approximately 18 versus 2%)."( Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats.
Dreifinger, T; Hoffman, A; Kagan, L; Mager, DE, 2010
)
0.89
" The oral bioavailability was approximately 52."( Validated HPLC method for quantitative determination of talinolol in rat plasma and application to a preclinical pharmacokinetic study.
Bhat, KM; Musmade, PB; Pathak, SM; Udupa, N, 2010
)
0.61
" In vivo study was conducted by quantitating the effect of orally administered DLX on the bioavailability of talinolol."( In vitro and in vivo evaluation of the effects of duloxetine on P-gp function.
Junhua, C; Ruike, Z; Wenxing, P, 2010
)
0.57
" In the in vivo study, co-administration of DLX increased the bioavailability of talinolol."( In vitro and in vivo evaluation of the effects of duloxetine on P-gp function.
Junhua, C; Ruike, Z; Wenxing, P, 2010
)
0.59
"An increase in the area under the curve (AUC) after oral digoxin due to coadministration of drugs known as P-glycoprotein (P-gp) inhibitors has been reported in several studies, but there is very little information on the rate of absorption after P-gp inhibition."( Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition.
Sermsappasuk, P; Siegmund, W; Weiss, M, 2012
)
0.38
"05) or kept unaltered the absorption rate constant (k(a) ) of SQV in function of the concentration of both compounds administered."( In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats.
Catalán-Latorre, A; Jiménez-Torres, NV; Merino, V; Merino-Sanjuán, M; Nácher, A, 2011
)
0.64
"To enhance the bioavailability of the poorly water-soluble drug talinolol, a self-nanoemulsifying drug delivery system (SNEDDS) comprising 5% (w/v) Brij-721 ethanolic solution (Smix), triacetin, and water, in the ratio of 40:20:40 (% w/w) was developed by constructing pseudo-ternary phase diagrams and evaluated for droplet size, polydispersity index, and surface morphology of nanoemulsions."( Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β₁-adrenoreceptor blocker Talinolol.
Ghai, D; Sinha, VR, 2012
)
0.82
"In this study, a self-nanoemulsifying drug delivery system was utilized to enhance the bioavailability of the poorly water-soluble beta-blocker talinolol."( Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β₁-adrenoreceptor blocker Talinolol.
Ghai, D; Sinha, VR, 2012
)
0.78
"Superior bioavailability of BCS Class 2 compounds incorporated into SNEDDS was previously reported."( Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.
Aldouby, Y; Cherniakov, I; Domb, AJ; Elgart, A; Hoffman, A, 2013
)
0.59
"Multiple mechanisms are accountable for improved bioavailability and reduced variability of Class-2 compounds by SNEDDS: increased solubilization, reduced intraenterocyte metabolism and reduced P-gp efflux."( Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol.
Aldouby, Y; Cherniakov, I; Domb, AJ; Elgart, A; Hoffman, A, 2013
)
0.59
" 2-Aminoquinoline-based scaffolds were designed with the hope that they could (a) mimic aminopyridines as potent, isoform-selective arginine isosteres and (b) possess chemical properties more conducive to oral bioavailability and CNS penetration."( Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
Chreifi, G; Cinelli, MA; Li, H; Martásek, P; Poulos, TL; Roman, LJ; Silverman, RB, 2014
)
0.4
" A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake."( High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Langguth, P; Nguyen, MA; Staubach, P; Tamai, I, 2015
)
0.85
" Promising members of our previously reported 2-aminoquinoline class of nNOS inhibitors, although orally bioavailable and brain-penetrant, suffer from unfavorable off-target binding to other CNS receptors, and they resemble known promiscuous binders."( Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
Cinelli, MA; Kang, S; Li, H; Martásek, P; Pensa, AV; Poulos, TL; Roman, LJ; Silverman, RB, 2015
)
0.42
" Increment of talinolol bioavailability upon low and high doses of barnidipine co-administration may be due to P-glycoprotein inhibition."( Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation.
Okyar, A; Ozturk, D; Ozturk, N; Pala-Kara, Z, 2017
)
1.14
" Pharmacokinetic studies indicate that 1 has an oral bioavailability with an average F-value of 27."( An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
Eslamimehr, S; Franzblau, SG; Kong, Y; Kurosu, M; Lemieux, MR; Mitachi, K; Park, F; Pressly, JD; Siricilla, S; Wang, Y; Yang, D, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"In order to clarify the effect of rifampicin on the bioavailability of the P-glycoprotein substrate talinolol, its absorption kinetics was modeled after multiple-dose oral administration of talinolol in healthy subjects."( Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.
D'Argenio, DZ; Siegmund, W; Weiss, M, 2022
)
1.15
"Rifampicin changes the time course of absorption rate but not the fraction absorbed of talinolol."( Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein Substrate Talinolol and Rifampicin.
D'Argenio, DZ; Siegmund, W; Weiss, M, 2022
)
1.15

Dosage Studied

The results show that talinolol administered once daily in a dosage of 200 - 300 mg/d is effective and safe in the management of chronic stable angina. PGP-mediated efflux appears to be a major factor responsible for GI region-specific absorption of talinole in rats.

ExcerptRelevanceReference
" dosage of rac-talinolol (30 mg and 100 mg, resp."( Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
Langguth, P; Mutschler, E; Rösch, W; Spahn-Langguth, H; Terhaag, B; Wetterich, U, 1996
)
0.88
" With regard to dTMW an increasing antihypertensive effect was determined for the dosage step from 50 mg to 100 mg talinolol/d."( [Antihypertensive action of various talinolol dosages after four week's treatment in comparison with placebo].
Herrmann, WM; Terhaag, B; Weigmann, I; Wierich, W, 1998
)
0.78
" While repetitive verapamil and talinolol dosing had no statistically significant exsorption-inducing effect, vinblastine and rifampicin pretreatments resulted in decreased intestinal talinolol permeabilities in the three tested gut segments, duodenum, jejunum, and colon [e."( Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats.
Hanafy, A; Langguth, P; Spahn-Langguth, H, 2001
)
0.59
" Data indicate that once-a-day dosing can be performed with less fluctuation between peak and trough for talinolol in comparison to atenolol."( Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
Derendorf, H; Schmidt, J; Sourgens, H, 2003
)
0.89
"The results show that talinolol administered once daily in a dosage of 200 - 300 mg/d is effective and safe in the management of chronic stable angina."( Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris.
Faulhaber, HD; Lang, U; Terhaag, B; Weigmann, I; Weinsberg, F, 2005
)
0.88
" As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.33
"The bioavailability of talinolol in term of AUC(0-->infinity) for IR talinolol was approximately twice as high as compared to the administration of the same dose in a controlled-release dosage form."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.64
"The present study demonstrates a considerable loss of bioavailability of drugs that are substrates of intestinal secretory transporters upon their administration in controlled-release dosage forms."( Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Böcher, WO; Langguth, P; Spahn-Langguth, H; Tubic, M; Wagner, D; Wanitschke, R; Weiler, C, 2006
)
0.33
" A sigmoid dose-response model was used to fit the data and to estimate the IC50 values of the potential inhibitors."( Polymethoxylated flavones and other phenolic derivates from citrus in their inhibitory effects on P-glycoprotein-mediated transport of talinolol in Caco-2 cells.
Butterweck, V; De Castro, WV; Derendorf, H; Manthey, JA; Mertens-Talcott, SU, 2007
)
0.54
" PGP-mediated efflux appears to be a major factor responsible for GI region-specific absorption of talinolol in rats, and gastroretentive dosage forms may provide an advantage in the delivery of talinolol and PGP substrate drugs."( Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats.
Dreifinger, T; Hoffman, A; Kagan, L; Mager, DE, 2010
)
0.81
" Moreover, the release properties of the dosage form should be known."( In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans.
Oswald, S; Siegmund, W; Terhaag, B, 2011
)
0.37
" Moreover, it is contained in highly dosed nutraceuticals available on the market."( High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.
Langguth, P; Nguyen, MA; Staubach, P; Tamai, I, 2015
)
0.66
" The pharmacokinetics of talinolol were measured after single oral dosing of 50-mg tablet and the pharmacokinetic parameters for male and female subjects were compared after excluding the potential influence of P-gp genetic polymorphisms."( No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans.
Chen, ZJ; Lin, Y; Long, B; Su, YQ; Tang, B; Xia, Y; Zou, YY, 2016
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency30.05340.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency10.28820.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.86640.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency20.56070.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.65720.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency22.38720.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.67680.000229.305416,493.5996AID1259244; AID1259248; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency23.12340.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency13.33320.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency30.04740.000323.4451159.6830AID743065; AID743067
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency14.38180.005612.367736.1254AID624032
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency8.41270.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency8.41270.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chymotrypsinogen ABos taurus (cattle)Ki0.90000.90004.00008.7000AID1510600
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.90000.00000.66359.5499AID1510600
Beta-1 adrenergic receptorHomo sapiens (human)Ki0.24000.00011.33919.9840AID1510599
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)2.80000.00000.54509.1000AID1510595
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Ki172.00000.11002.02675.5000AID681382
ATP-dependent translocase ABCB1Homo sapiens (human)Ki21,570.00003.40003.40003.4000AID681382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
digestionChymotrypsinogen ABos taurus (cattle)
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (119)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1407669Apparent permeability of the compound from basolateral to apical side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1243942Efflux ratio in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1635247Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1458739Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1407668Apparent permeability of the compound from apical to basolateral side in human Caco2 cells assessed as drug recovery after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID681382TP_TRANSPORTER: inhibition of Verapamil binding in membranes from Vinblastine-induced Caco-2 cells1999The Journal of pharmacology and experimental therapeutics, Jan, Volume: 288, Issue:1
Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
AID1510595Inhibition of recombinant human full length soluble epoxide hydrolase (1 to 555 residues) expressed in Escherichia coli BL21(DE3) using non-fluorescent PHOME as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins b2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID1365715Apparent permeability of the compound across basolateral side to apical side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1476988Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1195906Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID1510596Metabolic stability in Sprague-Dawley rat liver microsomes at 10 uM preincubated for 5 mins followed by NADPH addition and measured for 60 mins by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID1451287Apparent permeability across basolateral to apical side in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1254934Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs by LC-MS/MS method2015European journal of medicinal chemistry, Oct-20, Volume: 1033-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID1365728Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1195904Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID681334TP_TRANSPORTER: transepithelial transport in Caco 2 cell2004Pharmaceutical research, May, Volume: 21, Issue:5
Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo.
AID1365726Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1446780Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1261677Apparent permeability in human Caco2 cells across basolateral to apical side at 10 uM after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1261675Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1223492Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1400066Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1510599Binding affinity to beta1 adrenergic receptor (unknown origin) by radioligand binding assay2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID1458740Efflux ratio of apparent permeability across basolateral to apical over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1407667Apparent permeability of the compound from apical to basolateral side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1075512Apparent permeability across basolateral to apical side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID1482937Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID678834TP_TRANSPORTER: transepithelial transport in Caco-2 cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.
AID1458738Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors.
AID1075511Efflux ratio of apparent permeability across apical to basolateral side over basolateral to apical side in human Caco2 cells at 10 uM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID1407671Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1482929Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID1476987Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1510600Binding affinity to beta2 adrenergic receptor (unknown origin) by radioligand binding assay2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID1451288Efflux ratio of apparent permeability in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1365727Apparent permeability of the compound across basolateral side to apical side in human Caco2 cells monolayer at 10 uM after 1 hr by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1510597Permeability of the compound in PBS at 100 uM incubated for 16 hrs by artificial membrane permeability assay based UPLS-MS analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1446779Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1365716Efflux ratio of apparent permeability from basolateral to apical over apical to basolateral side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1476989Efflux ratio of apparent permeability from basolateral to apical side over apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM measured over 2 hrs by LC-MS/MS analysis2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.
AID1446781Efflux ratio of apparent permeability across basolateral to apical over apical to basolateral side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS method2017European journal of medicinal chemistry, Apr-21, Volume: 130Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1245599Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1243941Apparent permeability from basolateral side to apical side in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID1243940Apparent permeability from apical to basolateral side in human Caco2 cells2015European journal of medicinal chemistry, Aug-28, Volume: 101Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1451286Apparent permeability across apical to basolateral side in human Caco2 cells after 2 hrs by LC-MS/MS method2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Blockade of Asparagine Endopeptidase Inhibits Cancer Metastasis.
AID1400067Apparent permeability from basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1261678Apparent permeability in human Caco2 cells across apical to basolateral side at 10 uM after 2 hrs2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Phenyl Ether- and Aniline-Containing 2-Aminoquinolines as Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase.
AID1195905Apparent permeability across basolateral to apical side in human Caco2 cells at 10 uM after 2 hrs by LC/MS/MS analysis2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1510594Binding affinity to recombinant human C-terminal soluble epoxide hydrolase-hydrolase domain (222 to 555 residues) expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 200 uM by SYPRO orange dye-based differential scanning f2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID679067TP_TRANSPORTER: transepithelial transport of Talinolol at a concentration of 20 uM in Caco-2 cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID1510598Inhibition of soluble epoxide hydrolase in human HepG2 cells assessed as reduction in conversion of EET to DHET up to 1 uM using (+/-)14(15)-EET-d11 as substrate preincubated for 15 mins followed by substrate addition and measured after 10 mins by LC-MS/M2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Computer-Aided Selective Optimization of Side Activities of Talinolol.
AID1635246Apparent permeability from apical to basolateral side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1075513Apparent permeability across apical to basolateral side in human Caco2 cells at 10 microM for 2 hrs by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4
Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition.
AID1365714Apparent permeability of the compound across apical side to basolateral side in human Caco2 cells monolayer at 10 uM after 2 hrs by LC-MS/MS analysis2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
AID1635248Efflux ratio of apparent permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 10 uM incubated for 120 mins by LC-MS/MS analysis2016European journal of medicinal chemistry, Aug-08, Volume: 118Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
AID1407670Apparent permeability of the compound from basolateral to apical side in human Caco2 cells assessed as drug recovery after 120 mins by LC-MS/MS analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1400068Efflux ratio of apparent permeability in human Caco2 cells at 10 uM after 2 hrs by LC-MS/MS analysis2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
An antimycobacterial pleuromutilin analogue effective against dormant bacilli.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1482938Efflux ratio of apparent permeability across basolateral to apical side to apical to basolateral side in human Caco2 cells at 10 uM measured up to 2 hrs by ESI-LC/MS/MS analysis2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID679066TP_TRANSPORTER: transepithelial transport of Talinolol at a concentration of 20 uM in MDR1-expressing MDCK cells2003Pharmaceutical research, Aug, Volume: 20, Issue:8
Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (224)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (29.02)18.7374
1990's28 (12.50)18.2507
2000's61 (27.23)29.6817
2010's59 (26.34)24.3611
2020's11 (4.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.18 (24.57)
Research Supply Index5.66 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (19.58%)5.53%
Reviews6 (2.50%)6.00%
Case Studies9 (3.75%)4.05%
Observational0 (0.00%)0.25%
Other178 (74.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bioavailability of Paracetamol, Amoxicillin and Talinolol and Expression of Intestinal Drug Metabolizing Enzymes and Transport Proteins Before, Immediately and One Year After Proximal Roux-en-Y Gastric Bypass Operation in Patients With Morbid Adipositas [NCT02514941]Phase 112 participants (Actual)Interventional2007-06-30Completed
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water [NCT01635608]Phase 112 participants (Actual)Interventional2011-04-30Completed
Open Label Study for the Functional Characterization of Drug Metabolism and Transport [NCT01788254]Phase 1144 participants (Actual)Interventional2012-01-31Completed
Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics (TWINS II) [NCT01845194]Phase 1117 participants (Actual)Interventional2009-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]